Latest Conference

Dr. Nicola Petrosillo discusses treating C difficile infection and maintaining antimicrobial stewardship during the height of the COVID-19 pandemic in Italy.

Antimicrobial resistance is a growing problem that requires international collaboration to educate the general public and stakeholders, while simultaneously developing solutions.

Highlights from the sessions of the World Anti-Microbial Resistance Congress 2021 included addressing the global threat for AMR and looking at real world data and real world evidence to deter resistance.

Anti-microbial resistance is one of the most critical issues in healthcare, and the CDC and WHO addressed these concerns with plans to fight back against AMR at the annual world congress.

Results on this investigational antibiotic in its phase 2A study were presented at the C Diff. Conference today.

Presentation highlights from the second and final day of the 9th Annual International C. diff Conference & Health Expo.

Dr. Tamás Haidegger talks about his work to develop an AI-based scanner that tracks hand hygiene to prevent C difficile and other infections.

At the C Diff Foundation Conference, promising investigational modalities and therapies, as well as better treatment approaches are all being discussed in hopes of some real inroads being made in this field in the near future.

Although no longer indicated as a first-line therapy, metronidazole still has therapeutic benefits and can serve patients in certain settings and circumstances.

Highlights from the morning session of the C Diff Foundation Conference included data about Pfizer's investigational vaccine, insights about Seres Therapeutics microbiome therapeutic, and a look at CDI incidence rates around COVID-19.

Curtis Donskey, MD, discussed his efforts to encourage C. diff patients and providers to do their part to reduce infection and reinoculation.

The development of these programs are being looked at for private practices in the community settings to try to create better prescribing practices and avoid the potential progression to health care associated infections.

The organization is hosting its 9th Annual International C Diff Conference and Health EXPO on Thursday and Friday this week. The conference is virtual and free to the public.

A study found similar rates of acute respiratory illness-related visits across race/ethnicity when all healthcare settings were combined, but ARI visits differed for race/ethnicity groups across ambulatory, emergency, and hospital settings.

Learn more about new test for diagnosing early Lyme disease in a Q&A with Adaptive Biotechnologies.

Self-testing for HIV is fast and easy, and test kits can be completed at a health department with the help of staff or at home and dropped off later.

As more agents expand the capability and variety of PrEP options, investigators consider what questions remain about the drug class.

Following the approval of cabotegravir-rilpivirine earlier this year, experts are looking forward to an expansion of the drug class for HIV.

The combination therapy's non-inferior efficacy to heavier TAF regimens may indicate a greater embrace of 2-drug regimens for people living with HIV.

Monica McArthur, MD, PhD, discusses why to-be-authorized COVID-19 vaccine doses for children may not be tiered for patient risk as they were for adults.

New late-breaking data illuminate the specific efficacy of the combination monoclonal antibodies.

The findings have supported the launch of a phase 3 trial called EVERGREEN, which is now underway.

A conversation in consideration of the high-risk psychosocial comorbidities the aging HIV population may face through COVID-19.

A new study from IDWeek showed most observed children previously infected with SARS-CoV-2 retained antibodies over 6 months.

An expert reviews cabotegravir, islatravir, lenacapavir, and what other promising agents that could redefine long-term HIV prevention.

The COVID-19 pandemic led people to take hygiene and sanitation more seriously, causing a decrease in C difficile infections.

A clinician provides an overview of the data on the microbiota-based live biotherapeutic, RBX2660, which in phase 3 studies has shown safety and reduction in recurrent C difficile infection (rCDI).

After an initial hospitalization for COVID-19, some patients may have specific risk factors that increase their likelihood of readmittance.